Literature DB >> 33623018

Alternative splicing and cancer: a systematic review.

Yuanjiao Zhang1,2, Jinjun Qian2, Chunyan Gu3,4, Ye Yang5,6.   

Abstract

The abnormal regulation of alternative splicing is usually accompanied by the occurrence and development of tumors, which would produce multiple different isoforms and diversify protein expression. The aim of the present study was to conduct a systematic review in order to describe the regulatory mechanisms of alternative splicing, as well as its functions in tumor cells, from proliferation and apoptosis to invasion and metastasis, and from angiogenesis to metabolism. The abnormal splicing events contributed to tumor progression as oncogenic drivers and/or bystander factors. The alterations in splicing factors detected in tumors and other mis-splicing events (i.e., long non-coding and circular RNAs) in tumorigenesis were also included. The findings of recent therapeutic approaches targeting splicing catalysis and splicing regulatory proteins to modulate pathogenically spliced events (including tumor-specific neo-antigens for cancer immunotherapy) were introduced. The emerging RNA-based strategies for the treatment of cancer with abnormally alternative splicing isoforms were also discussed. However, further studies are still required to address the association between alternative splicing and cancer in more detail.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33623018      PMCID: PMC7902610          DOI: 10.1038/s41392-021-00486-7

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  213 in total

Review 1.  Pre-mRNA splicing: awash in a sea of proteins.

Authors:  Melissa S Jurica; Melissa J Moore
Journal:  Mol Cell       Date:  2003-07       Impact factor: 17.970

2.  Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus.

Authors:  X D Fu; T Maniatis
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

Review 3.  CRISPR-Cas13 Precision Transcriptome Engineering in Cancer.

Authors:  Javier T Granados-Riveron; Guillermo Aquino-Jarquin
Journal:  Cancer Res       Date:  2018-07-18       Impact factor: 12.701

4.  A Loss-of-Function Variant in a Minor Isoform of ANK3 Protects Against Bipolar Disorder and Schizophrenia.

Authors:  Timothy Hughes; Lars Hansson; Ida E Sønderby; Lavinia Athanasiu; Verena Zuber; Martin Tesli; Jie Song; Christina M Hultman; Sarah E Bergen; Mikael Landén; Ingrid Melle; Ole Andreas Andreassen; Srdjan Djurovic
Journal:  Biol Psychiatry       Date:  2015-11-11       Impact factor: 13.382

5.  EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.

Authors:  Ivan Babic; Erik S Anderson; Kazuhiro Tanaka; Deliang Guo; Kenta Masui; Bing Li; Shaojun Zhu; Yuchao Gu; Genaro R Villa; David Akhavan; David Nathanson; Beatrice Gini; Sergey Mareninov; Rui Li; Carolina Espindola Camacho; Siavash K Kurdistani; Ascia Eskin; Stanley F Nelson; William H Yong; Webster K Cavenee; Timothy F Cloughesy; Heather R Christofk; Douglas L Black; Paul S Mischel
Journal:  Cell Metab       Date:  2013-05-23       Impact factor: 27.287

6.  microRNA-mediated regulation of splicing factors SRSF1, SRSF2 and hnRNP A1 in context of their alternatively spliced 3'UTRs.

Authors:  Elżbieta Sokół; Hanna Kędzierska; Alicja Czubaty; Beata Rybicka; Katarzyna Rodzik; Zbigniew Tański; Joanna Bogusławska; Agnieszka Piekiełko-Witkowska
Journal:  Exp Cell Res       Date:  2018-01-10       Impact factor: 3.905

7.  Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells.

Authors:  Jan-Gowth Chang; Den-Mei Yang; Wen-Hsin Chang; Lu-Ping Chow; Wen-Ling Chan; Hui-Hua Lin; Hsien-Da Huang; Ya-Sian Chang; Cheng-Hao Hung; Wen-Kuang Yang
Journal:  PLoS One       Date:  2011-06-09       Impact factor: 3.240

8.  MYC Regulates α6 Integrin Subunit Expression and Splicing Under Its Pro-Proliferative ITGA6A Form in Colorectal Cancer Cells.

Authors:  Jean-François Groulx; Salah Boudjadi; Jean-François Beaulieu
Journal:  Cancers (Basel)       Date:  2018-02-03       Impact factor: 6.639

9.  SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.

Authors:  Yang Liang; Toma Tebaldi; Kai Rejeski; Poorval Joshi; Giovanni Stefani; Ashley Taylor; Yuanbin Song; Radovan Vasic; Jamie Maziarz; Kunthavai Balasubramanian; Anastasia Ardasheva; Alicia Ding; Alessandro Quattrone; Stephanie Halene
Journal:  Leukemia       Date:  2018-06-01       Impact factor: 11.528

10.  Alternative splicing and its impact as a cancer diagnostic marker.

Authors:  Yun-Ji Kim; Heui-Soo Kim
Journal:  Genomics Inform       Date:  2012-06-30
View more
  45 in total

Review 1.  A simple guide to de novo transcriptome assembly and annotation.

Authors:  Venket Raghavan; Louis Kraft; Fantin Mesny; Linda Rigerte
Journal:  Brief Bioinform       Date:  2022-03-10       Impact factor: 11.622

2.  PBX4 functions as a potential novel oncopromoter in colorectal cancer: a comprehensive analysis of the PBX gene family.

Authors:  Eirini G Martinou; Carla S Moller-Levet; Angeliki M Angelidi
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

Review 3.  Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics.

Authors:  Qiu Peng; Yujuan Zhou; Linda Oyang; Nayiyuan Wu; Yanyan Tang; Min Su; Xia Luo; Ying Wang; Xiaowu Sheng; Jian Ma; Qianjin Liao
Journal:  Mol Ther       Date:  2021-11-15       Impact factor: 11.454

Review 4.  Transcriptome analysis provides critical answers to the "variants of uncertain significance" conundrum.

Authors:  Mackenzie D Postel; Julie O Culver; Charité Ricker; David W Craig
Journal:  Hum Mutat       Date:  2022-05-18       Impact factor: 4.700

Review 5.  p53 Isoforms as Cancer Biomarkers and Therapeutic Targets.

Authors:  Liuqun Zhao; Suparna Sanyal
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

6.  Optimal CD8+ T cell effector function requires costimulation-induced RNA-binding proteins that reprogram the transcript isoform landscape.

Authors:  Timofey A Karginov; Antoine Ménoret; Anthony T Vella
Journal:  Nat Commun       Date:  2022-06-20       Impact factor: 17.694

Review 7.  PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.

Authors:  Joseph Walton; Keith Lawson; Panagiotis Prinos; Antonio Finelli; Cheryl Arrowsmith; Laurie Ailles
Journal:  Nat Rev Urol       Date:  2022-10-17       Impact factor: 16.430

8.  Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes.

Authors:  Deeksha Malhan; Alireza Basti; Angela Relógio
Journal:  NPJ Syst Biol Appl       Date:  2022-05-12

9.  Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-β pathway.

Authors:  Eunji Kang; Kanggeon Kim; Sook Young Jeon; Ji Gwang Jung; Hong-Kyu Kim; Han-Byoel Lee; Wonshik Han
Journal:  Cancer Gene Ther       Date:  2022-01-19       Impact factor: 5.854

10.  A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients.

Authors:  Rui Cheng; Lixing Xiao; Wenyang Zhou; Xiyun Jin; Zhaochun Xu; Chang Xu; Pingping Wang; Meng Luo; Mengyun Wang; Kexin Ma; Huimin Cao; Yan Huang; Xiaoyu Lin; Fenglan Pang; Yiqun Li; Qinghua Jiang
Journal:  Oncogene       Date:  2021-07-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.